视觉画布设计
canvas-design
基于设计原则创作静态视觉作品,用于海报与品牌图形。
pa-clinical-policy【文档与办公】Reasoning skill for prior authorization clinical policy evaluation. Use when the user asks about payer clinical criteria, step therapy requirements, medical necessity definitions, CMS LCD/NCD coverage rules, appeals documentation strategy, formulary tier implications, or FHIR Da Vinci PAS implementation guidance. Triggers include "prior auth policy",…
独立 GitHub 快照 · 自动分类 · 以原作者文档为准
Guide the agent through structured evaluation of prior authorization (PA) clinical policies, coverage determinations, step therapy protocols, and appeals processes. This skill encodes payer policy logic so the agent can assess whether a requested service meets authorization criteria, identify documentation gaps, and recommend appeal strategies.
When a user asks about a PA decision, follow this sequence:
Medical necessity requires ALL of the following:
| Condition | Requested Service | Required Criteria |
|---|---|---|
| Rheumatoid Arthritis | Biologic (TNF inhibitor) | Failure of ≥1 conventional DMARD (methotrexate) for ≥3 months |
| Multiple Sclerosis | Disease-modifying therapy | Confirmed MS diagnosis (McDonald criteria), relapse history |
| Chronic Pain | Opioid >90 MME/day | Pain management referral, urine drug screen, treatment agreement |
| Diabetes (Type 2) | GLP-1 receptor agonist | HbA1c ≥7% on metformin, or metformin contraindication documented |
| Cancer | PET/CT scan | Staging of newly diagnosed cancer or restaging after treatment |
| Sleep Apnea | CPAP device | AHI ≥5 on polysomnography, clinical symptoms documented |
Step therapy mandates that lower-cost or first-line treatments are tried before authorizing higher-cost alternatives. The general pattern:
Step 1: Generic / first-line therapy
↓ (documented failure, intolerance, or contraindication)
Step 2: Preferred brand / second-line therapy
↓ (documented failure, intolerance, or contraindication)
Step 3: Non-preferred / specialty therapy
| Drug Class | Step 1 | Step 2 | Step 3 |
|---|---|---|---|
| Statins | Generic atorvastatin/rosuvastatin | Preferred brand statin | PCSK9 inhibitor |
| Antidepressants | Generic SSRI (sertraline, fluoxetine) | Generic SNRI (venlafaxine) | Brand atypical (Trintellix) |
| Biologics (RA) | Methotrexate + conventional DMARD | Preferred TNF inhibitor | Non-preferred biologic/JAK inhibitor |
| Diabetes | Metformin | Sulfonylurea or SGLT2 | GLP-1 RA or insulin |
| Asthma | ICS (fluticasone) | ICS/LABA combination | Biologic (omalizumab, dupilumab) |
| Attribute | NCD (National) | LCD (Local) |
|---|---|---|
| Issuer | CMS central | Medicare Administrative Contractor (MAC) |
| Scope | All Medicare nationwide | MAC jurisdiction (A/B or DME) |
| Override | Cannot be overridden locally | Must comply with any applicable NCD |
| Appeal path | ALJ → Medicare Appeals Council → Federal court | Redetermination → QIC → ALJ |
| Update frequency | Infrequent (years) | More frequent (annual review) |
When assessing whether a service is covered under an LCD:
| Level | Action | Timeline | Decision Maker |
|---|---|---|---|
| 1 | Internal appeal | 30 days (standard), 72 hours (expedited) | Payer medical director |
| 2 | External review | 45 days (standard), 72 hours (expedited) | Independent Review Organization (IRO) |
| 3 | State regulatory | Varies by state | Department of Insurance |
| Level | Action | Timeline |
|---|---|---|
| 1 | Plan redetermination | 7 days (expedited), 30 days (standard) |
| 2 | Independent Review Entity (IRE) | 7 days (expedited), 30 days (standard) |
| 3 | Administrative Law Judge (ALJ) | Amount in controversy ≥$180 (2024) |
| 4 | Medicare Appeals Council | No minimum amount |
| 5 | Federal District Court | Amount in controversy ≥$1,760 (2024) |
When preparing for a peer-to-peer review with the payer medical director:
The Da Vinci Prior Authorization Support (PAS) Implementation Guide defines a FHIR-based workflow for submitting and tracking prior authorization requests. CMS mandates payer support by 2026.
Bundle with Claim + supporting resources$submit operation to payer's PAS endpointClaimResponse with disposition: approved, denied, or pendedCommunicationRequestBundle with requested documentationClaimResponse$inquire operation for status updatesWrong: Assuming all payers use the same clinical criteria for a given service Right: Always check the specific payer's published clinical policy before submitting a PA request Why: Each payer maintains independent policies; criteria that work for one payer may not apply to another
Wrong: Skipping step therapy documentation when the patient tried a drug at a prior plan Right: Document all prior treatments with dates, doses, duration, and outcomes — even from previous plans Why: Without documented evidence of prior steps, the payer will deny regardless of actual treatment history
Wrong: Submitting appeals without addressing the specific denial reason code or cited criteria Right: Reference the exact denial reason and provide evidence directly addressing each unmet criterion Why: Generic appeals that don't target the specific denial rationale are almost always upheld
Wrong: Applying an LCD from one MAC jurisdiction to a provider in a different MAC's territory Right: Identify the correct MAC jurisdiction for the provider's location and use that MAC's LCD Why: LCDs are jurisdiction-specific; coverage rules from one MAC have no authority in another
Wrong: Treating LCDs and NCDs as equivalent or interchangeable Right: Always check for an applicable NCD first — NCDs take precedence and cannot be overridden by LCDs Why: An LCD cannot contradict or override a National Coverage Determination
Wrong: Missing formulary exception deadlines, especially for expedited requests Right: Track and meet all turnaround requirements — 24 hours for expedited exceptions Why: Missed deadlines result in automatic denials and delayed patient access to needed medications
Wrong: Conducting peer-to-peer reviews without citing published clinical guidelines Right: Reference specific society guidelines (ACR, NCCN, AAN) that support the requested service Why: Peer-to-peer reviews are significantly more effective when backed by authoritative guideline citations
Wrong: Attaching clinical documentation as unstructured PDFs in Da Vinci PAS bundles
Right: Structure clinical documentation in the supportingInfo field using proper FHIR resource references
Why: Unstructured attachments cannot be processed by automated adjudication systems, causing delays
Wrong: Applying commercial appeal timelines and processes to Medicare PA requests Right: Use Medicare-specific appeal levels and timelines (redetermination → IRE → ALJ → MAC → Federal court) Why: Medicare has distinct appeal levels, timelines, and amount-in-controversy thresholds
Wrong: Failing to track PA expiration dates after authorization is granted Right: Monitor authorization validity periods and reauthorize before expiration if services are ongoing Why: Services rendered after PA expiration require new authorization — retroactive approval is rarely granted
Is the service on the payer's PA-required list?
├── NO → No PA needed; proceed with service
└── YES
├── Is there an applicable NCD?
│ ├── YES → Does the request meet NCD criteria?
│ │ ├── YES → Approve (document NCD compliance)
│ │ └── NO → Deny (cite NCD; appeal to ALJ if Medicare)
│ └── NO → Check for LCD or plan-specific policy
│ ├── LCD exists → Evaluate LCD criteria
│ └── Plan policy exists → Evaluate plan criteria
│ ├── Medical necessity met?
│ │ ├── YES → Check step therapy
│ │ │ ├── Step therapy satisfied → Approve
│ │ │ └── Step therapy NOT satisfied
│ │ │ ├── Exception applies? → Approve with exception
│ │ │ └── No exception → Deny (cite step therapy)
│ │ └── NO → Deny (cite medical necessity)
│ └── Documentation incomplete?
│ └── Pend for additional information
| Category | CARC Code Range | Example | Recommended Action |
|---|---|---|---|
| Medical necessity not met | 50, 56 | Diagnosis does not support service | Appeal with clinical evidence |
| Step therapy not completed | 149 | Required prior drug not tried | Document prior treatments |
| Not a covered benefit | 96, 97 | Service excluded from plan | Formulary exception or plan change |
| Documentation insufficient | 16, 252 | Missing clinical notes | Resubmit with complete records |
| Experimental/investigational | 56 | Off-label use not approved | Cite peer-reviewed evidence |
| Out of network | 151 | Provider not in network | Network exception or referral |
| Duplicate authorization | 18 | PA already exists for service | Verify existing PA status |
| Request Type | Commercial (typical) | Medicare Part C | Medicare Part D |
|---|---|---|---|
| Standard (non-urgent) | 15 calendar days | 14 calendar days | 72 hours (standard) |
| Expedited (urgent) | 72 hours | 72 hours | 24 hours |
| Retrospective | 30 calendar days | 30 calendar days | N/A |
| Extension (pend for info) | +14 days (one extension) | +14 days | +14 days |
A request qualifies as expedited when:
| Limit Type | Description | Example |
|---|---|---|
| Per-fill limit | Maximum units per prescription fill | 30-day supply for controlled substances |
| Per-period limit | Maximum units over a time period | 9 fills per year for triptan medications |
| Lifetime limit | Maximum total units ever | Gene therapy — single administration |
| Diagnosis-based limit | Quantity varies by condition | Higher opioid limits for cancer pain |
Payers increasingly require lower-cost sites for infusion and injection therapies:
Is the drug available for home infusion?
├── YES → Home infusion preferred (lowest cost)
│ ├── Patient clinically stable? → Approve home infusion
│ └── Patient requires monitoring? → Approve outpatient infusion center
└── NO → Is outpatient infusion center available?
├── YES → Outpatient preferred over hospital outpatient
└── NO → Hospital outpatient department approved
| Date | Regulation | Impact |
|---|---|---|
| Jan 2024 | CMS Interoperability Rule (CMS-0057-F) finalized | Payers must implement FHIR PAS API |
| Jan 2026 | FHIR PAS API mandate effective | Payers must accept electronic PA via Da Vinci PAS |
| Jan 2026 | PA decision transparency | Payers must provide specific denial reasons and applicable criteria |
Several states require payers to exempt providers from PA if they demonstrate ≥90% approval rate for a specific service over 12 months. Exemption lasts 12 months, subject to audit, and is revoked if approval rate drops below threshold.